vs
Ginkgo Bioworks Holdings, Inc.（DNA）与First Bancorp, Inc（FNLC）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是First Bancorp, Inc的1.3倍（$33.4M vs $25.8M），First Bancorp, Inc同比增速更快（17.5% vs -23.8%），First Bancorp, Inc自由现金流更多（$34.6M vs $-47.7M），过去两年First Bancorp, Inc的营收复合增速更高（18.1% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
第一银行公司（First Bancorp, Inc）是一家银行控股公司，其核心业务通过总部位于康涅狄格州斯坦福的爱国者国家银行（Patriot Bank NA）开展，相关 banking 业务也以PNBK代码在纳斯达克挂牌交易。
DNA vs FNLC — 直观对比
营收规模更大
DNA
是对方的1.3倍
$25.8M
营收增速更快
FNLC
高出41.4%
-23.8%
自由现金流更多
FNLC
多$82.3M
$-47.7M
两年增速更快
FNLC
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $25.8M |
| 净利润 | — | $10.2M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 48.1% |
| 净利率 | — | 39.4% |
| 营收同比 | -23.8% | 17.5% |
| 净利润同比 | — | 39.7% |
| 每股收益（稀释后） | $-1.41 | $0.91 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAFNLC
| Q4 25 | $33.4M | $25.8M | ||
| Q3 25 | $38.8M | $24.5M | ||
| Q2 25 | $49.6M | $22.5M | ||
| Q1 25 | $48.3M | $21.8M | ||
| Q4 24 | $43.8M | $22.0M | ||
| Q3 24 | $89.0M | $20.5M | ||
| Q2 24 | $56.2M | $19.2M | ||
| Q1 24 | $37.9M | $18.5M |
净利润DNAFNLC
| Q4 25 | — | $10.2M | ||
| Q3 25 | $-80.8M | $9.1M | ||
| Q2 25 | $-60.3M | $8.1M | ||
| Q1 25 | $-91.0M | $7.1M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | $-56.4M | $7.6M | ||
| Q2 24 | $-217.2M | $6.2M | ||
| Q1 24 | $-165.9M | $6.0M |
营业利润率DNAFNLC
| Q4 25 | -211.9% | 48.1% | ||
| Q3 25 | -231.8% | 45.2% | ||
| Q2 25 | -132.1% | 43.7% | ||
| Q1 25 | -184.1% | 39.3% | ||
| Q4 24 | -236.3% | 39.5% | ||
| Q3 24 | -62.0% | 44.6% | ||
| Q2 24 | -396.7% | 38.8% | ||
| Q1 24 | -469.1% | 39.3% |
净利率DNAFNLC
| Q4 25 | — | 39.4% | ||
| Q3 25 | -207.9% | 37.0% | ||
| Q2 25 | -121.6% | 35.8% | ||
| Q1 25 | -188.2% | 32.5% | ||
| Q4 24 | — | 33.1% | ||
| Q3 24 | -63.3% | 36.9% | ||
| Q2 24 | -386.4% | 32.1% | ||
| Q1 24 | -437.3% | 32.5% |
每股收益（稀释后）DNAFNLC
| Q4 25 | $-1.41 | $0.91 | ||
| Q3 25 | $-1.45 | $0.81 | ||
| Q2 25 | $-1.10 | $0.72 | ||
| Q1 25 | $-1.68 | $0.63 | ||
| Q4 24 | $-1.91 | $0.66 | ||
| Q3 24 | $-1.08 | $0.68 | ||
| Q2 24 | $-4.23 | $0.55 | ||
| Q1 24 | $-3.32 | $0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | — |
| 总债务越低越好 | — | $95.5M |
| 股东权益账面价值 | $508.6M | $283.1M |
| 总资产 | $1.1B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资DNAFNLC
| Q4 25 | $422.6M | — | ||
| Q3 25 | $495.5M | — | ||
| Q2 25 | $559.4M | — | ||
| Q1 25 | $325.3M | — | ||
| Q4 24 | $561.6M | — | ||
| Q3 24 | $616.2M | — | ||
| Q2 24 | $730.4M | — | ||
| Q1 24 | $840.4M | — |
总债务DNAFNLC
| Q4 25 | — | $95.5M | ||
| Q3 25 | — | $95.5M | ||
| Q2 25 | — | $95.0M | ||
| Q1 25 | — | $70.0M | ||
| Q4 24 | — | $95.0M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | — | $70.0M | ||
| Q1 24 | — | $70.0M |
股东权益DNAFNLC
| Q4 25 | $508.6M | $283.1M | ||
| Q3 25 | $559.8M | $274.6M | ||
| Q2 25 | $613.0M | $265.5M | ||
| Q1 25 | $647.4M | $259.7M | ||
| Q4 24 | $716.1M | $252.5M | ||
| Q3 24 | $797.9M | $256.8M | ||
| Q2 24 | $833.1M | $244.7M | ||
| Q1 24 | $987.3M | $242.6M |
总资产DNAFNLC
| Q4 25 | $1.1B | $3.2B | ||
| Q3 25 | $1.2B | $3.2B | ||
| Q2 25 | $1.2B | $3.2B | ||
| Q1 25 | $1.3B | $3.2B | ||
| Q4 24 | $1.4B | $3.2B | ||
| Q3 24 | $1.5B | $3.1B | ||
| Q2 24 | $1.6B | $3.1B | ||
| Q1 24 | $1.6B | $3.0B |
负债/权益比DNAFNLC
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $37.8M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $34.6M |
| 自由现金流率自由现金流/营收 | -142.8% | 133.9% |
| 资本支出强度资本支出/营收 | 0.0% | 12.5% |
| 现金转化率经营现金流/净利润 | — | 3.72× |
| 过去12个月自由现金流最近4个季度 | — | $55.3M |
8季度趋势，按日历期对齐
经营现金流DNAFNLC
| Q4 25 | $-47.7M | $37.8M | ||
| Q3 25 | $-31.6M | $12.9M | ||
| Q2 25 | $-40.3M | $7.4M | ||
| Q1 25 | $-51.5M | $2.2M | ||
| Q4 24 | $-42.4M | $26.0M | ||
| Q3 24 | $-103.5M | $9.8M | ||
| Q2 24 | $-84.4M | $6.4M | ||
| Q1 24 | $-89.3M | $-1.5M |
自由现金流DNAFNLC
| Q4 25 | $-47.7M | $34.6M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | $-40.3M | $7.2M | ||
| Q1 25 | $-59.1M | $828.0K | ||
| Q4 24 | $-56.1M | $24.6M | ||
| Q3 24 | $-118.6M | $9.6M | ||
| Q2 24 | $-111.4M | $6.3M | ||
| Q1 24 | $-96.0M | $-1.8M |
自由现金流率DNAFNLC
| Q4 25 | -142.8% | 133.9% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | -81.2% | 32.1% | ||
| Q1 25 | -122.4% | 3.8% | ||
| Q4 24 | -128.0% | 111.7% | ||
| Q3 24 | -133.2% | 47.0% | ||
| Q2 24 | -198.2% | 32.9% | ||
| Q1 24 | -252.9% | -9.8% |
资本支出强度DNAFNLC
| Q4 25 | 0.0% | 12.5% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.1% | 0.6% | ||
| Q1 25 | 15.8% | 6.2% | ||
| Q4 24 | 31.3% | 6.7% | ||
| Q3 24 | 16.9% | 0.5% | ||
| Q2 24 | 48.1% | 0.3% | ||
| Q1 24 | 17.7% | 1.8% |
现金转化率DNAFNLC
| Q4 25 | — | 3.72× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
FNLC
暂无分部数据
